Judge, Sarah M et al. identified MEF2C as a key upstream transcription factor required to maintain MyoC expression in skeletal muscle, MEF2C gain-of-function inhibits the downregulated of MyoC and prevents skeletal muscle wasting and dysfunction caused by cancer (Judge et al., 2020). The gene discussed is MYOC; the disease is cancer.